{"entity":{"id":"nct07082803","kind":"trial","name":"TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas","aka":[],"tldr":"A phase 1 trial of TLN-121 run by Treeline Biosciences, Inc., now recruiting.","summary":"TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas is a phase 1 interventional study registered as NCT07082803 by Treeline Biosciences, Inc., with 180 participants planned, started 2025-06-23. Conditions recorded: Lymphoma and Lymphoma, Non Hodgkin. Interventions recorded: TLN-121, zeprumetostat (TLN-254) and TLN-121.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07082803","url":"https://clinicaltrials.gov/study/NCT07082803"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tln-121","zeprumetostat"],"companies":["treeline-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07082803","phase":"1","setting":"An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas","sponsor":"Treeline Biosciences, Inc.","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07082803/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"tln-121","kind":"drug","name":"TLN-121","route":"/drugs/tln-121/"},{"id":"zeprumetostat","kind":"drug","name":"Zeprumetostat","route":"/drugs/zeprumetostat/"}],"company":[{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/"}]}}